Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

被引：113
|
作者：
Krystof, Vladimir [1 ,2 ]
Baumli, Sonja [3 ]
Fuerst, Robert [4 ]
机构：
[1] Palacky Univ, Lab Growth Regulators, Fac Sci, Olomouc 78371, Czech Republic
[2] Inst Expt Bot ASCR, Olomouc 78371, Czech Republic
[3] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[4] Univ Munich, Dept Pharm, Ctr Drug Res Pharmaceut Biol, D-81377 Munich, Germany
来源：
CURRENT PHARMACEUTICAL DESIGN | 2012年 / 18卷 / 20期
基金：
英国医学研究理事会;
关键词：
Cancer; inflammation; kinase; P-TEFb; inhibitor; therapeutics; angiogenesis; FLAVOPIRIDOL INDUCES APOPTOSIS; GROWTH-FACTOR EXPRESSION; MULTIPLE-MYELOMA CELLS; P-TEFB; TRANSCRIPTION ELONGATION; KAPPA-B; DOWN-REGULATION; CDK9/CYCLIN T1; SELICICLIB CYC202; CRYSTAL-STRUCTURE;
D O I：
10.2174/138161212800672750
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.
引用
收藏
页码：2883 / 2890
页数：8
相关论文
共 50 条
  • [11] Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor
    Albert, T. K.
    Rigault, C.
    Eickhoff, J.
    Baumgart, K.
    Antrecht, C.
    Klebl, B.
    Mittler, G.
    Meisterernst, M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (01) : 55 - 68
  • [12] Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity
    Wang, Jubo
    Li, Tinghan
    Zhao, Tengteng
    Wu, Tizhi
    Liu, Chuang
    Ding, Hong
    Li, Zhiyu
    Bian, Jinlei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 178 : 782 - 801
  • [13] CDK9 a potential target for drug development
    Canduri, Fernanda
    Peres, Patricia Cardoso
    Caceres, Rafael Andrade
    de Azevedo, Walter Filgueira, Jr.
    MEDICINAL CHEMISTRY, 2008, 4 (03) : 210 - 218
  • [14] Cell Cycle-Dependent Kinase Cdk9 Is a Postexposure Drug Target against Human Adenoviruses
    Prasad, Vibhu
    Suomalainen, Maarit
    Hemmi, Silvio
    Greber, Urs F.
    ACS INFECTIOUS DISEASES, 2017, 3 (06): : 398 - 405
  • [15] Cyclin-dependent kinase 9: a potential therapeutic target for esophageal adenocarcinoma
    Tong, Zhimin
    Chatterjee, Devkumar
    Deng, Defeng
    Veeranki, Omkara
    Mejia, Alicia
    Rodriguez, Jaime
    Ajani, Jaffer
    Hofstetter, Wayne
    Lin, Steven
    Guha, Sushovan
    Kopetz, Scott
    Krishnan, Sunil
    Maru, Dipen
    CANCER RESEARCH, 2016, 76
  • [16] Cyclin K Inhibits HIV-1 Gene Expression and Replication by Interfering with Cyclin-dependent Kinase 9 (CDK9)-Cyclin T1 Interaction in Nef-dependent Manner
    Khan, Sohrab Zafar
    Mitra, Debashis
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (26) : 22943 - 22954
  • [17] Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway
    Ni, Weiyu
    Zhang, Feizhou
    Zheng, Lin
    Wang, Lili
    Liang, Yi
    Ding, Yuhong
    Yik, Jasper H. N.
    Haudenschild, Dominik R.
    Fan, Shunwu
    Hu, Ziang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [18] PRT2527, a novel highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, is active in preclinical models of prostate cancer.
    Federici, Elisa
    Civenni, Gianluca
    Kokanovic, Aleksandra
    Sandrini, Giada
    Guarrera, Luca
    Mosole, Simone
    Cacciatore, Alessia
    Uboldi, Valeria
    Lessi, Manuel
    Papa, Giovanni
    Albino, Domenico
    Storelli, Elisa
    Merulla, Jessica
    Rinaldi, Andrea
    Bolis, Marco
    Zhang, Yang
    Vaddi, Kris
    Scherle, Peggy
    Ruggeri, Bruce
    Carbone, Giuseppina M.
    Catapano, Carlo V.
    CANCER RESEARCH, 2022, 82 (12)
  • [19] Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer sternness activity against non-small-cell lung cancer
    Wang, Xin
    Yu, Chenhua
    Wang, Cheng
    Ma, Yakun
    Wang, Tianqi
    Li, Yao
    Huang, Zhi
    Zhou, Mangian
    Sun, Peiqing
    Zheng, Jianyu
    Yang, Shengyong
    Fan, Yan
    Xiang, Rong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 181
  • [20] Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy
    Karati, Dipanjan
    Mahadik, Kaka Saheb Ramoo
    Trivedi, Piyush
    Kumar, Dileep
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (04) : 383 - 403
12345